Why Heart Failure Treatment Starts with Medications, Not Surgery
When patients come to me after a new diagnosis of heart failure, their first question is often about surgery. Will they need a new valve? A bypass? A heart transplant? These are understandable concerns. But the honest answer, in most cases, is that the single most important intervention we can offer is something far less dramatic: getting you on the right medications, at the right doses, as quickly as possible.
This is what cardiologists and cardiac surgeons refer to as guideline-directed medical therapy, or GDMT. It is the backbone of modern heart failure treatment, supported by decades of randomized clinical trials and endorsed by the American College of Cardiology (ACC) and American Heart Association (AHA). These medications reduce hospitalizations, improve symptoms, and — most critically — extend life.
Yet here is the problem: research consistently shows that fewer than one in four eligible heart failure patients are receiving all recommended medications at their target doses. A 2022 analysis published in JAMA Cardiology found that optimization of GDMT remains alarmingly low across the United States, even at academic medical centers. That gap between what guidelines recommend and what patients actually receive is, frankly, one of the most important issues in cardiology today.
As a cardiac surgeon, I operate on the consequences of undertreated heart failure regularly. I want you to understand what these drugs are, why they work, and how to advocate for yourself if you feel your medical therapy has not been fully optimized.
The Four Pillars of HFrEF GDMT Therapy
Heart failure comes in different forms. The type most relevant to this discussion is heart failure with reduced ejection fraction (HFrEF), meaning the heart's main pumping chamber — the left ventricle — is weakened and not squeezing as effectively as it should. An ejection fraction (EF) of 40% or below generally qualifies. Normal is typically 55-70%.
For HFrEF, the ACC/AHA guidelines identify four foundational classes of heart failure medications. These are sometimes called the "four pillars" of GDMT:
1. Renin-Angiotensin System Inhibitors (ARNI or ACE Inhibitor or ARB)
The preferred agent in this category is sacubitril/valsartan (brand name Entresto), a combination drug known as an angiotensin receptor-neprilysin inhibitor (ARNI). The landmark PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced cardiovascular death by 20% and heart failure hospitalization by 21% compared with the older standard, enalapril.
If an ARNI is not tolerated or accessible, an ACE inhibitor (such as enalapril or lisinopril) or an ARB (such as losartan or valsartan) should be used instead. But the guidelines are clear: an ARNI is preferred when feasible.
2. Beta-Blockers
Not all beta-blockers are created equal in heart failure. Only three have proven mortality benefit in HFrEF: carvedilol, metoprolol succinate (the extended-release form), and bisoprolol. These medications slow the heart rate, reduce the toxic effects of chronic adrenaline stimulation on the heart muscle, and have been shown to reduce mortality by approximately 30-35% in major trials (MERIT-HF, COPERNICUS, CIBIS-II).
A common mistake I see is patients being placed on a beta-blocker that is not one of these three evidence-based options, or being kept at a low dose indefinitely without attempts to titrate upward.
3. Mineralocorticoid Receptor Antagonists (MRAs)
Spironolactone and eplerenone fall into this category. The RALES trial showed that spironolactone reduced mortality by 30% in patients with severe heart failure. These are potent medications that block aldosterone, a hormone that drives harmful remodeling of the heart. They require monitoring of kidney function and potassium levels, but they are generally well tolerated and significantly underused.
4. SGLT2 Inhibitors
This is the newest pillar, and arguably the most exciting development in heart failure treatment in the past decade. Dapagliflozin (Farxiga) and empagliflozin (Jardiance) — originally developed as diabetes medications — have shown remarkable benefits in heart failure regardless of whether the patient has diabetes. The DAPA-HF and EMPEROR-Reduced trials demonstrated significant reductions in cardiovascular death and heart failure hospitalization. These drugs work through mechanisms that are still being fully elucidated, but their clinical impact is undeniable.
Current guidelines from 2022 onward recommend SGLT2 inhibitors for essentially all patients with HFrEF. If you have not been offered one, it is worth asking your cardiologist why.
Why So Many Patients Are Not on Optimal Heart Failure Medications
If these drugs are so effective, why are the majority of patients not receiving the full regimen at target doses? The reasons are multiple and worth understanding, because recognizing them can help you be a more effective advocate for your own care.
- Therapeutic inertia. This is the clinical term for a common phenomenon: a patient is started on a low dose of a medication, tolerates it well, but the dose is never increased at follow-up visits. Studies suggest this is the single largest contributor to suboptimal GDMT.
- Side effect concerns. Each of these medication classes can cause side effects — low blood pressure, elevated potassium, kidney function changes, dizziness. Some physicians are understandably cautious. But the evidence overwhelmingly shows that the benefits of reaching target doses outweigh the risks for most patients.
- Fragmented care. If you see a primary care physician, a general cardiologist, and occasionally a heart failure specialist, the question of who is responsible for titrating your medications can fall through the cracks.
- Cost and access. Sacubitril/valsartan and SGLT2 inhibitors can be expensive, and insurance coverage varies. Patient assistance programs exist for both, but navigating them takes effort.
- Patient factors. Sometimes patients stop medications because of side effects without informing their physician, or they are reluctant to add another pill to an already complex regimen.
None of these are insurmountable problems. But they require attention, communication, and sometimes a fresh set of eyes on your treatment plan.
When Heart Failure Treatment Moves Beyond Medications
GDMT is the foundation, but it is not always sufficient. When heart failure progresses despite optimized medical therapy, or when there is a specific structural problem contributing to heart failure, surgical and device-based options enter the conversation.
These may include:
- Cardiac resynchronization therapy (CRT) — a specialized pacemaker for patients with specific electrical conduction delays and reduced EF.
- Implantable cardioverter-defibrillator (ICD) — for patients at risk of life-threatening arrhythmias.
- Coronary artery bypass grafting (CABG) — when ischemic heart disease is a significant contributor to heart failure. The STICH trial demonstrated a long-term survival benefit for CABG in selected patients with HFrEF and significant coronary disease.
- Valve surgery or intervention — particularly for severe mitral regurgitation, which can both cause and worsen heart failure.
- Left ventricular assist devices (LVADs) — for advanced heart failure as a bridge to transplant or as long-term destination therapy.
- Heart transplantation — the definitive treatment for end-stage heart failure in appropriate candidates.
The critical point is this: surgery should generally not be pursued until GDMT has been fully optimized. I have seen patients referred for major cardiac operations whose medication regimens had obvious gaps — missing an SGLT2 inhibitor, on a subtherapeutic dose of a beta-blocker, never tried on an ARNI. In some of these cases, optimizing medications first can improve heart function enough to change the risk-benefit calculus of surgery entirely.
This is one of the most important things I evaluate when reviewing cases for a cardiac surgery second opinion. Is the recommended procedure truly necessary right now, or has the medical foundation not yet been fully built?
How to Know If Your Heart Failure Medication Regimen Is Optimized
Here are practical steps you can take:
- Know your ejection fraction. Ask your doctor for the number from your most recent echocardiogram. If your EF is 40% or below, you should be on all four pillars of GDMT unless there is a documented reason you cannot tolerate one.
- Ask about target doses. For each medication you are taking, ask whether you are at the guideline-recommended target dose. If not, ask what the plan is to get there.
- Request a medication reconciliation. Bring all your medications — including over-the-counter drugs and supplements — to every appointment. Make sure nothing is working at cross-purposes.
- Ask about referral to a heart failure specialist. General cardiologists provide excellent care, but if your heart failure is worsening or your medications are difficult to manage, a dedicated heart failure cardiologist may be able to offer additional expertise.
- Use objective tools. If surgery has been recommended, our free cardiac surgery risk calculator can help you understand your estimated procedural risk and put it in context with your overall treatment plan.
Understanding your medications is not about second-guessing your physician. It is about being an informed participant in your own care. The best outcomes in heart failure come from a true partnership between patient and medical team.
A Note About Heart Failure with Preserved Ejection Fraction (HFpEF)
If your ejection fraction is above 50% but you still have heart failure symptoms, you may have HFpEF. The treatment landscape here is different and historically has had fewer proven pharmacologic options. However, SGLT2 inhibitors have now demonstrated benefit in HFpEF as well (EMPEROR-Preserved and DELIVER trials), and the guidelines increasingly support their use across the full spectrum of heart failure. Discuss this with your cardiologist if it applies to you.
When a Second Opinion Changes the Plan
I review cardiac surgery cases every week where the question is not just "Is this operation technically feasible?" but "Is this operation the right next step for this patient at this time?" In heart failure, that question cannot be answered without a careful look at the patient's medication regimen, their trajectory, and whether GDMT has been given a real chance to work.
Sometimes a second opinion confirms the surgical recommendation and gives the patient confidence to move forward. Other times, it identifies opportunities to optimize medical therapy first, potentially avoiding or delaying a high-risk operation. Both outcomes serve the patient.
You can learn more about how our review process works and what is included in a comprehensive case evaluation.
If you are facing a recommendation for cardiac surgery and want to ensure your heart failure treatment has been fully optimized, a WhiteGloveMD second opinion can help. Our reviews are conducted by a board-certified cardiovascular surgeon and include a thorough analysis of your medical therapy, imaging, and surgical risk. Start your review today and get the clarity you need to make the best possible decision for your heart.